Buy, Sell, or Hold This Generic Pharma Titan?

Teva Pharmaceuticals company is struggling as its largest profit source dries up, yet it's certainly not failing.

Jun 27, 2014 at 5:00PM

Teva Pharmaceuticals (NYSE:TEVA) is the world's largest generic-drug maker. Somewhat ironically for a company that specializes in generics, its business is struggling at the moment as its own blockbuster patent-protected drug, Copaxone, just lost its patent protection in the U.S.

Two teams of competitive pharmaceutical companies with generics businesses are launching their own version of Copaxone as Teva's patent expires. One team consists of Mylan (NASDAQ:MYL) and India's Natco, while the other is driven by Momenta Pharmaceuticals (NASDAQ:MNTA) and Novartis (NYSE:NVS).

Those partnerships are willing to take on Teva with their own versions of Copaxone despite Teva's own incredibly strong generics business. That's a clear sign that they believe there's still some profit to be had from the drug, even as its patent-granted exclusivity expires.

Still, Teva's core generics business remains profitable, and it was that generics business that first made Teva an attractive pick for the real-money Inflation-Protected Income Growth portfolio. In the slideshow below, portfolio manager Chuck Saletta reviews Teva in light of the Copaxone patent loss and determines whether he'd be willing to buy more, hold on, or part ways with the generic pharmaceutical giant.

Teva Pharmaceuticals: Buy, Sell, or Hold? from The Motley Fool.

Generics drive consistency, but innovation in health care drives profits
Teva's lasting strength comes from its generics business and the reality that people will always need medication and want the lowest costs. Still, the biggest profits in the industry come from investing in disruptive technologies before they hit it big.

Right now, there is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multibagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

To follow the iPIG portfolio as buy and sell decisions are made, watch Chuck's article feed by clicking here. To join The Motley Fool's free discussion board dedicated to the iPIG portfolio, click here. To see the iPIG portfolio's online tracking spreadsheet, click here.

Chuck Saletta owns shares of Teva Pharmaceutical Industries. The Motley Fool recommends Momenta Pharmaceuticals and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.